Renato Mantegazza

Italian Association for Cancer Research — Italy

Medicine · Health Sciences

66h-index16.4kcitations530works5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myasthenia Gravis and Thymoma(269), Peripheral Neuropathies and Disorders(120), Parkinson's Disease and Spinal Disorders(72), Muscle Physiology and Disorders(47), Antifungal resistance and susceptibility(45)

Publications521 total

Does myasthenia gravis impact cognitive functioning? A systematic review and meta-analysis
Neurological Sciences·2026
463PRefractory myasthenia gravis - clinical course and predictive factors in a large cohort of patients
Neuromuscular Disorders·2025
459PClinical meaning of PROMs in a large cohort of myasthenia gravis patients
Neuromuscular Disorders·2025Open Access
Use of Corticosteroids in Myasthenia Gravis: Expert Opinion for Daily Management
Neurology and Therapy·2025· 5 citedOpen Access
Unknown Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis
Neurology Neuroimmunology & Neuroinflammation·2025· 8 citedOpen Access
Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
UNC Libraries·2025Open Access
Eculizumab improves fatigue in refractory generalized myasthenia gravis
UNC Libraries·2025Open Access
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
UNC Libraries·2025Open Access
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
UNC Libraries·2025Open Access
Caregiving burden among caregivers of people with myasthenia gravis
Orphanet Journal of Rare Diseases·2025· 1 citedOpen Access
Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice
Frontiers in Immunology·2025Open Access
278th ENMC International Workshop: European standards for harmonization of myasthenia gravis registries and emerging digital solutions. 20th-21st September 2024, Hoofddorp, The Netherlands
Neuromuscular Disorders·2025
A cost analysis of reductions in work productivity for MG patients and their caregivers by symptom severity
Frontiers in Public Health·2025· 1 citedOpen Access
<scp>ADAPT NXT</scp>: Fixed Cycles or Every‐Other‐Week <scp>IV</scp> Efgartigimod in Generalized Myasthenia Gravis
Annals of Clinical and Translational Neurology·2025· 7 citedOpen Access
Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT (P1-11.004)
Neurology·2025
Combined Analyses of Participants with Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated with Efgartigimod Across Clinical Studies (P1-11.029)
Neurology·2025
Oral Cladribine Capsules for Generalized Myasthenia Gravis: Design of the Actively Recruiting Phase 3 MyClad Study (P1-11.013)
Neurology·2025
Long-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P1-11.005)
Neurology·2025
COVID-19 Vaccination Response in Participants Across Clinical Trials Investigating Efgartigimod PH20 SC (P9-11.029)
Neurology·2025
Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension
European Journal of Neurology·2025· 10 citedOpen Access
page 1 of 27Next →

Frequent Co-authors

Pia Bernasconi(17), Carlo Antozzi(16), F. Cornelio(14), James F. Howard(10), Paolo Confalonieri(10), Fulvio Baggi(9), Kimiaki Utsugisawa(8), Tuan Vu(8), Lorenzo Maggi(8), Marina Mora(8), Hiroyuki Murai(7), John Vissing(7), Francesca Andreetta(7), Lucía Morandi(7), Vera Bril(6), Henry J. Kaminski(6), Isabel Illa(5), Saiju Jacob(5), Srikanth Muppidi(5), Richard J. Nowak(5)